Efficacy News and Research

RSS

Advaxis submits protocol revision for ADXS-HPV CIN Phase II study

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.

26 Jul 2011

Promising drug for Duchenne muscular dystrophy

Duchenne muscular dystrophy is a severely debilitating and lethal condition that affects 1 in 3,000. Females and males are affected, though females are rarely affected and are more often carriers. It is caused due to a defective gene that normally codes for the protein dystrophin, which helps provide a protective membrane around muscle fibers. Without this skin, muscle fibers become damaged and eventually die.

25 Jul 2011

Enrollment commences in Lutonix LEVANT 2 drug-coated balloon IDE trial for PAD

Lutonix today announced the first patient enrolled in the LEVANT 2 clinical trial, a global, multicenter, randomized trial evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon compared to a standard angioplasty balloon for the treatment of peripheral arterial disease (PAD). The first case was performed at St. John's Hospital in Springfield, IL by Dr. Jeff Goldstein.

25 Jul 2011

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.

25 Jul 2011

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Threshold Pharmaceuticals, Inc., today announced that the University of Texas at San Antonio initiated a clinical trial of TH-302 in combination with bevacizumab in patients with recurrent high grade astrocytoma including glioblastoma.

25 Jul 2011

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Biogen Idec announced today it has received conditional approval from the European Commission for FAMPYRA® (prolonged-release fampridine tablets) to improve walking in adult patients with multiple sclerosis who have walking disability.

25 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

BioDelivery Sciences International, Inc. announced today that the last patient has completed the randomized portion of its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain, signifying completion of the trial.

25 Jul 2011

Combination strategies more effective for reducing population of tiger mosquitos

An experimental research carried out in Sant Cugat del Vall-s and Rub-, coordinated by researchers from UAB, assessed the efficacy of a combination of strategies to reduce the population of tiger mosquitos.

25 Jul 2011

PNH patients applaud pan-Canadian approach to providing equitable access to Soliris

The Canadian Association of PNH Patients applauds governments across Canada for their landmark agreement to provide public access to Soliris (eculizumab), a life-saving treatment for the ultra-rare blood disease known as paroxysmal nocturnal haemoglobinuria.

25 Jul 2011

Circumcision prevents HIV transmission & cocktail of anti-HIV drugs prolong life

Reports came in last Wednesday that circumcision reduces transmission of HIV, in regions where transmission is high. To researchers, this procedure proves to be a cost-effective way to handle the pandemic. In South Africa, a study reported that men with circumcisions reduced new HIV infections by 76%.

24 Jul 2011

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Canadians newly diagnosed with a life-threatening blood cancer, chronic myeloid leukemia (CML) in chronic phase, now have a new treatment option available to them. Health Canada has granted a notice of compliance with conditions for SPRYCEL (dasatinib) as first-line treatment in patients with chronic phase CML.

22 Jul 2011

Combination of strategies reduces more than half the number of tiger mosquitos

The combination of three complementary measures to eradicate tiger mosquitos - avoid having stagnant water, using insecticides to eliminate larvae and adults, and removing rubbish - reduces more than half the number of tiger mosquitos, according to a research coordinated by researchers at Universitat Autonoma de Barcelona.

22 Jul 2011

Roche's cobas KRAS Mutation Test for colorectal cancer now available in Europe

Roche announced today that the cobas KRAS Mutation Test is now commercially available in Europe for use in colorectal cancer.

22 Jul 2011

Social safety net programs also reduce childhood obesity

Social safety net programs that reduce psychosocial stressors for low-income families also ultimately lead to a reduction in childhood obesity, according to research by a University of Illinois economist who studies the efficacy of food assistance programs on public health.

22 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011

Australian anti-cancer company completes $2.6 million placement

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today said it completed a private placement to raise $2 million from new and existing private and institutional investors in Australia. Investors have agreed to purchase 5,200,000 shares in the company at a price of $0.50 cents per share resulting in gross proceeds of $2.6 million.

21 Jul 2011

Neovasc to fund Tiara project with $4 million private placement

Neovasc Inc. today announced that it intends to complete a non-brokered private placement with accredited investors of up to four million equity units at the price of $1.00 per unit for aggregate gross proceeds of up to $4.0 million. The company expects that insiders will purchase approximately half of the units.

21 Jul 2011

Medco enters definitive merger agreement with Express Scripts

Express Scripts, Inc. and Medco Health Solutions, Inc. today announced that they have entered into a definitive merger agreement.

21 Jul 2011

Children and adults with social withdrawal due to Fragile X may benefit from STX209

Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists at Rush Children's Hospital at Rush University Medical Center.

21 Jul 2011

Efficacy News and Research

Advaxis submits protocol revision for ADXS-HPV CIN Phase II study

Promising drug for Duchenne muscular dystrophy

Enrollment commences in Lutonix LEVANT 2 drug-coated balloon IDE trial for PAD

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

Combination strategies more effective for reducing population of tiger mosquitos

PNH patients applaud pan-Canadian approach to providing equitable access to Soliris

Circumcision prevents HIV transmission & cocktail of anti-HIV drugs prolong life

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Combination of strategies reduces more than half the number of tiger mosquitos

Roche's cobas KRAS Mutation Test for colorectal cancer now available in Europe

Social safety net programs also reduce childhood obesity

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Australian anti-cancer company completes $2.6 million placement

Neovasc to fund Tiara project with $4 million private placement

Medco enters definitive merger agreement with Express Scripts

Children and adults with social withdrawal due to Fragile X may benefit from STX209

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News